XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaboration and Licensing Agreements (Tables)
 9 Months Ended
Sep. 30, 2024
Collaboration and Licensing Agreements  
Schedule of Revenue by Licensees
The revenues recorded for the three and nine months ended September 30, 2024 and 2023 were earned principally from the following licensees (in millions):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
(As Restated)
(As Restated)
Alexion$15.7 $31.8 $42.1 $53.4 
Gilead— 6.0 — 6.0 
Janssen— 13.7 — 41.1 
Mabgeek
— — 1.5 — 
MorphoSys/Incyte2.1 2.7 6.5 6.6 
Omeros— 5.0 — 5.0 
Vega— — 0.5 — 
Vir— — 0.1 1.5 
Zenas— — — 10.0 
Third Party Licensee
— — 7.0 — 
Total$17.8 $59.2 $57.7 $123.6 
Schedule of Disaggregation of Revenue
The table below summarizes the disaggregation of revenue recorded for the three and nine months ended September 30, 2024 and 2023 (in millions):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
(As Restated)
(As Restated)
Research collaboration$— $(1.3)$— $21.1 
License
— — 8.5 — 
Milestone— 46.0 0.5 61.0 
Royalties— 14.5 0.1 41.5 
Non-cash royalties17.8 — 48.6 — 
Total$17.8 $59.2 $57.7 $123.6